EUVIMEDEUVIMED entdecken
CrossrefInfokarte

SLV‐404, an anti‐RYK antibody–drug conjugate, is effective in Richter transformation patient‐derived xenografts

Matilde Micillo, Beatrice Pirajno, Francesco Edoardo Vallone, Victor Navarro‐Tableros, Elisabetta Bolli, Valentina Griggio, Brian J. Lannutti, Katti A. Jessen, Tiziana Vaisitti, Silvia Deaglio

HemaSphere · 2026-10 · 10 (10)

DOI: 10.1002/hem3.70478 ↗
AbstractBibliografische Angaben

Abstract

Abstract Richter transformation (RT), a highly aggressive lymphoma arising from a preexisting chronic lymphocytic leukemia, represents a major unmet clinical need. Recent data have shown that an antibody–drug conjugate (ADC) targeting the cell‐surface pseudokinase ROR1 is effective in RT patients. In this work, we explored other members of the ROR1 family and focused on RYK as a novel therapeutic target. Transcriptomic analyses revealed that RYK is expressed across multiple lymphoma subtypes, including indolent and aggressive lymphomas, such as RT, while it is absent in peripheral blood mononuclear cells (PBMCs) from healthy donors. To increase the selectivity of the ADC for highly proliferating B‐cell malignancies, as a payload we chose an inhibitor of topoisomerase I (TOP1), which is highly expressed in aggressive lymphomas while being undetectable in PBMCs from healthy donors. Based on these premises, we generated SLV‐404, an ADC composed of a chimeric antibody directed against the extracellular domain of RYK, a cleavable linker, and the potent TOP1 inhibitor deruxtecan (DXd). In vitro studies in lymphoma cell lines and in cells obtained from RT patient‐derived xenografts (RT‐PDXs) consistently showed robust induction of apoptosis following SLV‐404 treatment, while normal PBMCs were fully resistant. The antitumor activity of SLV‐404 was then confirmed in vivo using subcutaneous and intravenous RT‐PDX models. Treated animals survived significantly longer with markedly reduced tumor growth and tumor burden. Together, these findings identify RYK as a therapeutic target in aggressive RT and underline the potential of SLV‐404 as an ADC‐based strategy for the treatment of aggressive lymphomas.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →